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We thank Drs Carvalho and Schricker for their comments on our study. Both groups received the same doses of antibiotics, vasopressors, and nitroglycerin. No difference occurred in the use of blood products between the groups. The difference in postoperative weight gain did not result from excess fluid administration in the non-GIK patients because fluid management strategies were identical for both groups. In fact, the amount of fluid administered to both groups did not differ. We hypothesize that the decreased weight gain that was observed in the GIK patients was caused by better renal protection and improved systemic endothelial function. This improvement resulted in less capillary leakage, which accounts for the increased fluid accumulation seen in patients with diabetes who underwent CABG.
All patients were examined by our endocrine service, and their glucose management was optimized before they were discharged. No difference in the incidence of insulin use was noted between the 2 groups at discharge. Patients were observed subsequently by their own internists and endocrinologists.
Carvalho and Schricker contend that withholding insulin treatment until blood glucose exceeds 250 mg/dL does not constitute the standard of care, and we agree. They must realize, however, that this was the standard of care for cardiac surgery patients in most centers in the early 1990s, when our study was initiated. It is only recently that both cardiologists and cardiac surgeons, based on studies such as this 1 and the DIGAMI trial, 2 have begun to understand the importance of glycemic control during acute coronary syndromes and myocardial revascularization. In fact, one might argue that the non-GIK group did well because no difference in the 30-day mortality or the incidence of myocardial infarctions was found between the groups. GIK was beneficial during the immediate postoperative period in reducing weight gain, improving myocardial performance, and decreasing arrhythmias. These benefits were reflected in the improved long-term survival of the GIK group, which is similar to that seen in both the DIGAMI trial 2 and a meta-analysis of trials with GIK during acute myocardial infarctions. 3 We suspect that the enhanced long-term survival seen in patients who received perioperative GIK resulted from improved endothelial preservation in vein grafts in areas of ischemic myocardium, thus preventing further deterioration of myocardial function.
